Conclusions
MDD, depressive symptoms
This RCT found that application of the DPWG guidelines in TCA treatment of MDD could be safely applied and resulted in faster attainment of therapeutic plasma concentrations. No effect on depressive symptoms was found. The results of this study imply that the benefits of preemptive pharmacogenetic testing may vary between antidepressants. Therefore, further research that takes into account specific gene-antidepressant interactions with clinical outcomes is necessary.